One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2025-11-28
DOI
https://doi.org/10.1007/s12325-025-03422-1
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants

Paola Pellanda, Yuki Otani, Christopher D. Payne, Edward V. Loftus et al.
Advances in Therapy
Rheumatoid Arthritis Research and Therapies
article

One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants

Paola Pellanda, Yuki Otani, Christopher D. Payne, Edward V. Loftus, Geert D’Haens, Shomron Ben‐Horin, Abhishek Upadhya K, Galen H. Shi, Xin Zhang, Kristin Todd
article en

Abstract

No abstract available for this paper.
Advances in TherapyVol. 43(1)
Eli Lilly (United States) (US), Sheba Medical Center (IL), Mayo Clinic in Arizona (US), Amsterdam University Medical Centers (NL)
Openalex Percentile: Top 47%
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.